116 related articles for article (PubMed ID: 22466918)
21. Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).
Calza L; Magistrelli E; Colangeli V; Borderi M; Bussini L; Bon I; Re MC; Viale P
Infect Dis (Lond); 2017 Oct; 49(10):737-747. PubMed ID: 28683645
[TBL] [Abstract][Full Text] [Related]
22. Non-nucleoside reverse transcriptase inhibitors (NNRTIs)-induced Stevens-Johnson syndrome and gynecomastia in an HIV-infected child: A case report.
Saka B; Akakpo AS; Bassowa A; Dapam AN; Mahamadou G; Teclessou JN; Mouhari-Toure A; Laouali AY; Mensah E; Kombaté K; Pitché P
Ann Dermatol Venereol; 2018 Dec; 145(12):773-776. PubMed ID: 30301570
[TBL] [Abstract][Full Text] [Related]
23. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
van Leth F; Lange JM
Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943
[TBL] [Abstract][Full Text] [Related]
24. Severe eye complications from toxic epidermal necrolysis following initiation of Nevirapine based HAART regimen in a child with HIV infection: a case from Cameroon.
Tchetnya X; Ngwasiri CA; Munge T; Aminde LN
BMC Pediatr; 2018 Mar; 18(1):108. PubMed ID: 29534693
[TBL] [Abstract][Full Text] [Related]
25. Weight and body shape changes in a treatment-naive population after 6 months of nevirapine-based generic highly active antiretroviral therapy in South India.
Saghayam S; Kumarasamy N; Cecelia AJ; Solomon S; Mayer K; Wanke C
Clin Infect Dis; 2007 Jan; 44(2):295-300. PubMed ID: 17173234
[TBL] [Abstract][Full Text] [Related]
26. Abacavir-induced fulminant hepatic failure in a HIV/HCV co-infected patient.
Haas C; Ziccardi MR; Borgman J
BMJ Case Rep; 2015 Dec; 2015():. PubMed ID: 26670894
[TBL] [Abstract][Full Text] [Related]
27. [Exanthema simulating measles without measles virus? Allergic reaction to a non-nucleoside reverse transcriptase inhibitor in an HIV infected boy treated with HAART].
Lackmann GM; Schmidt B; Niehues T
Hautarzt; 2003 Aug; 54(8):765-6. PubMed ID: 12942192
[No Abstract] [Full Text] [Related]
28. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.
Swaminathan S; Padmapriyadarsini C; Venkatesan P; Narendran G; Ramesh Kumar S; Iliayas S; Menon PA; Selvaraju S; Pooranagangadevi NP; Bhavani PK; Ponnuraja C; Dilip M; Ramachandran R
Clin Infect Dis; 2011 Oct; 53(7):716-24. PubMed ID: 21890776
[TBL] [Abstract][Full Text] [Related]
29. Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine therapy.
Clarke S; Harrington P; Condon C; Kelleher D; Smith OP; Mulcahy F
Int J STD AIDS; 2000 May; 11(5):336-7. PubMed ID: 10824944
[TBL] [Abstract][Full Text] [Related]
30. Toxicity of non-nucleoside analogue reverse transcriptase inhibitors.
Kontorinis N; Dieterich DT
Semin Liver Dis; 2003 May; 23(2):173-82. PubMed ID: 12800070
[TBL] [Abstract][Full Text] [Related]
31. Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy.
Senise JF; Castelo A; Martínez M
AIDS Rev; 2011; 13(4):198-213. PubMed ID: 21975356
[TBL] [Abstract][Full Text] [Related]
32. Liver injury in HIV-1-infected patients receiving non-nucleosides reverse transcriptase inhibitors-based antiretroviral therapy.
Li ZC; Li HJ; Dai LL; Gao YQ; Cai WP; Li HY; Huang XJ; Zhang T; Wu H
Chin Med J (Engl); 2010 Dec; 123(24):3587-90. PubMed ID: 22166636
[TBL] [Abstract][Full Text] [Related]
33. [Hepatotoxicity with antiretroviral therapy. The liver is affected as well].
MMW Fortschr Med; 2002 Apr; 144 Suppl 1():14-5. PubMed ID: 12043064
[No Abstract] [Full Text] [Related]
34. Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy.
Giacomelli A; Riva A; Falvella FS; Oreni ML; Cattaneo D; Cheli S; Renisi G; Di Cristo V; Lupo A; Clementi E; Rusconi S; Galli M; Ridolfo AL
BMC Infect Dis; 2018 Nov; 18(1):556. PubMed ID: 30419834
[TBL] [Abstract][Full Text] [Related]
35. Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients.
Núñez M; González-Requena D; González-Lahoz J; Soriano V
AIDS Res Hum Retroviruses; 2003 Mar; 19(3):187-8. PubMed ID: 12689410
[TBL] [Abstract][Full Text] [Related]
36. Fulminant hepatic failure associated with antiretroviral therapy in a pregnant woman.
Stohl HE; Silva AM; Argani CH; Anderson JR
Int J Gynaecol Obstet; 2009 Sep; 106(3):260-1. PubMed ID: 19477440
[No Abstract] [Full Text] [Related]
37. Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.
Shahar E; Krivoy N; Weltfriend S; Pollack S
Jpn J Infect Dis; 2004 Oct; 57(5):212-3. PubMed ID: 15507779
[TBL] [Abstract][Full Text] [Related]
38. Livolin ameliorates elevations in alanine transaminase in HIV infected patients commencing highly active antiretroviral therapy.
Otegbayo JA; Kuti MA; Ogunbode O; Irabor AE; Adewoles IF
Afr J Med Med Sci; 2012 Dec; 41(4):417-22. PubMed ID: 23672107
[TBL] [Abstract][Full Text] [Related]
39. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.
Phillips E; Gutiérrez S; Jahnke N; Yip B; Lima VD; Hogg RS; Harrigan PR; Montaner JS
AIDS; 2007 Jul; 21(12):1561-8. PubMed ID: 17630551
[TBL] [Abstract][Full Text] [Related]
40. Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment.
de Maat MM; ter Heine R; van Gorp EC; Mulder JW; Mairuhu AT; Beijnen JH
AIDS; 2003 Oct; 17(15):2209-14. PubMed ID: 14523278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
